“An injectable, subcutaneous form of buprenorphine (CAM2038, Braeburn Pharmaceuticals) demonstrated noninferiority to sublingual buprenorphine tablets for opioid use disorder (OUD) in new research findings.
Results of a randomized phase 3 efficacy and safety trial show that the drug, which can be administered weekly or monthly, may be a second injectable option for improving adherence and reducing misuse of the drug.
“The advantage of this is you get a nice sustained blood level of buprenorphine over the duration of its intended exposure, either weekly or monthly. This potentially eliminates the need for the transmucosal buprenorphine, which a lot of practitioners are always concerned about in terms of diversion potential,” said coauthor Michelle Lofwall, MD, of the University of Kentucky in Lexington.
The results were presented at the American Academy of Addiction Psychiatry (AAAP) 28th Annual Meeting.”
Read more at: https://www.medscape.com/viewarticle/890463
Source: Medscape.com (login required) – December 21, 2017